Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
公司代码SGHT
公司名称Sight Sciences Inc
上市日期Jul 15, 2021
CEOBadawi (Paul)
员工数量216
证券类型Ordinary Share
年结日Jul 15
公司地址4040 Campbell Ave,
城市MENLO PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94025
电话14158890550
网址https://www.sightsciences.com/
公司代码SGHT
上市日期Jul 15, 2021
CEOBadawi (Paul)